Skip to main content
editor@theusajournals.com | Oscar Publishing Services Journal Home
Login

International Journal of Medical Sciences And Clinical Research

Peer Reviewed | Open Access | E-ISSN: 2771-2265
Published Article

Effect of Cardiac Glycosides on Myocardial Hibernation in Ischemic Heart Disease

Effect of Cardiac Glycosides on Myocardial Hibernation in Ischemic Heart Disease

Authors

  • Abdullaeva Ch.A.
    Tashkent State Medical University, Uzbekistan
  • Irisov J.B.
    Tashkent State Medical University, Uzbekistan
  • Zaxidova M.U..
    Tashkent State Medical University, Uzbekistan
  • Juraev M.I.
    Tashkent State Medical University, Uzbekistan
  • Mullaeva S.I.
    Tashkent State Medical University, Uzbekistan

DOI:

https://doi.org/10.37547/ijmscr/Volume06Issue01-06

Keywords:

Chronic heart failure inotropic stimulation cardiac glycosides

Abstract

A total of 30 patients with ischemic heart disease complicated by chronic heart failure (CHF) were enrolled in the study. In nearly all patients, CHF of a moderate functional class according to the NYHA classification was observed. At rest, echocardiographic examination assessed the following main parameters: left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), stroke volume (SV), and left ventricular ejection fraction (EF).

In patients with ischemic heart disease complicated by CHF, inotropic stimulation of the left ventricle by cardiac glycosides leads to a significant reduction in end-diastolic volume and dimensions. An overall and segmental increase in ejection fraction indicates the reversibility of left ventricular myocardial reserve function.

References

Amosova E.N. (2001) Sovremennye metody lecheniya bol'nykh, perenesshikh infarkt miokarda, i vtorichnaya profilaktika obostreniya ishemicheskoi bolezni serdtsa. Ukr. kardiol. zhurn., 4: 97–104.

Belenkov Yu.N., Ageev F.T., Mareev V.Yu. Znakom'tes': diastolicheskaya serdechnaya nedostatochnost'. Serd. nedost., 2000; 2: 58–61.

Belenkov Yu.N. Rol' narushenii sistoly i diastoly v razvitii serdechnoi nedostatochnosti. Ter. arkhiv, 2000; 9: 3–7.

Dolzhenko M.M., Potapov S.V., Fedotov S.V. (2001) Postinfarktnaya ishemiya miokarda: prospektivnye dostizheniya remodelirovaniya levogo zheludochka. Ukr. kardiol. zhurn., 5: 28–33.

Dyadyk A.I., Bagrii A.E. Vliyanie razlichnykh doz Veroshpirona na postinfarktnoe remodelirovanie levogo zheludochka. Ukr. kardiol. zhurn., 2003, №2 (34) – III/IV: 79–83.

Dyadyk A.I., Bagrii A.E. Sovremennye podkhody k lecheniyu patsientov, perenesshikh infarkt miokarda. Ukr. kardiol. zhurn., 2002, №1: 19–31.

Martynov A.I., Vasyuk Yu.A., Kopeleva N.V., Krikulov P.V. Postinfarktnoe remodelirovanie levogo zheludochka: vozmozhnosti beta-blokatorov. Kardiologiya, 2002, №3: 61–64.

Ol'binskaya L.I., Sizova Zh.M. Khronicheskaya serdechnaya nedostatochnost'. Monografiya. Moskva: «Reafarm», 2001; 344 s.

Parkhomenko A.N., Irkin O.I. Postinfarktnoe remodelirovanie serdtsa: patogenez i podkhody k optimizatsii terapii. Ukr. kardiol. zhurn., 2002, №6: 29–38.

Sledzevskaya I.K., Babii L.N., Savitskii S.Yu., Stroganova N.P., Fisenko L.I. Remodelirovanie levogo zheludochka i prognoz techeniya ishemicheskoi bolezni serdtsa u bol'nykh, perenesshikh infarkt miokarda v zavisimosti ot nalichiya arterial'noi gipertenzii. Ukr. kardiol. zhurn., 2002, №2: 14–18.

Tarasov N.I., Sizova I.N., Malakhovich E.V., Barbarash O.L. Znachenie pokazatelei vnutriserdechnoi i legochnoi gemodinamiki v razlichnye periody infarkta miokarda dlya rannei diagnostiki postinfarktnogo remodelirovaniya serdtsa. Ros. kardiol. zhurn., 2001, №1: 20–22.

憬 Florya V.G. (1997) Rol' remodelirovaniya levogo zheludochka v patogeneze khronicheskoi nedostatochnosti krovoobrashcheniya. Kardiologiya, 5: 63–69.

憬 Abbate A., Biondi-Zoccai G.G.L., Bussani R. et al. (2003) Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J. Am. Coll. Cardiol., 41: 753–760.

Banerjee P, Banerjee T, Khand A, et al. Diastolic heart failure; neglected or misdiagnosed& JASS 2002; 39; 138-141.

Braunwald E., Antman E.M., Beasley J.W. et al. (2002) ACC/ AHA 2002 Guideline update for the management of patients with unstable angina and non-ST-segment elevation Myocardial Infarction. J. Am. Coll. Cardiol., 40: 1366–1374.

Cicoira M., Zanolla L., Rossi A. et al. (2002) Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J. Am. Coll. Cardiol., 40: 304–310.

Chatterjee K. Primary diastolic heart failure. Am J Geriatr Cardiol 2002; 11; 178- 187.

Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications; a consensus paper from an international forum on cardiac remodeling/ JACC 2000;35;569-582.

Farquharson C.A.J., Struthers A.D. (2000) Spironolactone increases nitric oxide bioavailability, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation, 101: 594–597.

Hunt S.A., Baker D.W., Chin M.H. et al. (2001) ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol., 38: 2101–2113.